慢性中性粒细胞白血病（CNL）是一种克隆性疾病，其特征是成熟中性粒细胞增多。集落刺激因子 3 受体 (CSF3R) T618I 突变经常在 CNL 患者中被发现，并被定义为该疾病的分子标志物。 Ruxolitinib 是一种 JAK2 抑制剂，在 II 期研究中提供了有希望的治疗效果。特别是，鲁索替尼对于 CSF3R 突变的患者更有效。同种异体干细胞移植（Allo-SCT）可能是 CNL 的一种治疗方法。另一方面，还需要进一步研究来确定最佳的移植方法、供体来源、预处理治疗和移植时机。慢性嗜酸性粒细胞白血病 (CEL) 是一种克隆性疾病，其特征是嗜酸性粒细胞增多。世界卫生组织分类第五版更新了 CEL 的诊断标准。由于新标准比旧版本中的标准更具体地针对 CEL，因此从疾病名称中删除了“未另行指定 (NOS)”。抗 CD52 抗体阿仑单抗或抗 IL-5 抗体美泊利单抗是控制与嗜酸性粒细胞增多综合征相关症状的有前途的药物。 Allo-SCT 有望成为 CEL 的治愈性治疗方法，但 Allo-SCT 治疗 CEL 的证据仍然有限。需要进一步研究来确定治疗策略。

Chronic neutrophilic leukemia (CNL) is a clonal disorder that is characterized by increasing mature neutrophils. Colony stimulating factor 3 receptor (CSF3R) T618I mutation was frequently identified in patients with CNL and is defined as a molecular marker of the disease. Ruxolitinib, a JAK2 inhibitor, provided a promising therapeutic effect in a phase II study. In particular, ruxolitinib was more efficient for patients with CSF3R mutation. Allogeneic stem cell transplantation (Allo-SCT) may be a curative treatment for CNL. On the other hand, further studies are needed to define the optimal method of transplantation, source of donor, conditioning therapy, and timing of transplantation. Chronic eosinophilic leukemia (CEL) is a clonal disorder that is characterized by increasing eosinophils. In the World Health Organization Classification 5th edition, diagnostic criteria for CEL are renewed. Because the new criteria will be more specific for CEL than criteria in the older edition, "not otherwise specified (NOS) " is removed from the name of the disease. Anti-CD52 antibody, alemtuzumab, or anti-IL-5 antibody, mepolizumab, are promising drugs to control symptoms that are associated with hypereosinophilic syndrome. Allo-SCT is anticipated as a curative treatment for CEL, but the evidence of Allo-SCT for CEL is still limited. Further study is required to define the treatment strategy.